1. Tvardi's shares fell over 80% after Phase 2 trial results. 2. The trial assessed TTI-101 for idiopathic pulmonary fibrosis and failed to meet goals. 3. Faruqi & Faruqi is investigating claims for investors with significant losses. 4. Preliminary data showed similar patient characteristics across treatment groups. 5. Legal options are available for affected investors to discuss their rights.
FAQ
Why Very Bearish?
The 80% drop following trial failures severely undermines investor confidence, similar to past biotech crashes.
How important is it?
The article highlights serious legal and financial implications for Tvardi and its investors.
Why Short Term?
Immediate investor reactions to trial results and company investigations will likely affect price volatility shortly.
Tvardi Therapeutics Faces Investigation After Dramatic Share Price Drop
NEW YORK, Dec. 20, 2025 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a prominent national securities law firm, is launching an investigation into potential claims on behalf of investors in Tvardi Therapeutics, Inc. (NASDAQ: TVRD). This comes after the company experienced a staggering decline of over 80% in its stock price following disappointing results from its Phase 2 clinical trial.
Significant Losses in Tvardi Stock
On October 13, 2025, Tvardi's share price plummeted following the release of preliminary data from its REVERT clinical trial of TTI-101, aimed at treating idiopathic pulmonary fibrosis. This study was designed to evaluate the safety of the drug, along with pharmacokinetics and exploratory lung function outcomes. However, after assessing the initial data, the Company determined it had failed to achieve its objectives, which has prompted concern among investors.
Details of the Clinical Trial Findings
The preliminary findings indicated that the baseline characteristics of patients were comparable across treatment groups, except for a notable difference in forced vital capacity (FVC), which was lower in patients receiving the placebo compared to those given TTI-101. This lack of positive outcomes raises questions about the potential for future success in the ongoing development of TTI-101.
Investor Support Available
For investors who have incurred significant losses in TVRD stock or options, Faruqi & Faruqi partner Josh Wilson encourages them to reach out for assistance. Investors can contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
About Faruqi & Faruqi, LLP
Founded in 1995, Faruqi & Faruqi has established a remarkable track record, recovering hundreds of millions of dollars for investors in various securities disputes. The firm operates nationally, offering services from its offices in New York, Pennsylvania, California, and Georgia. To learn more about the ongoing investigation regarding TVRD, visit www.faruqilaw.com/TVRD.
Stay Informed
For updates on this investigation and other relevant news, follow Faruqi & Faruqi on LinkedIn, X, or Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
All communications will be treated confidentially, and the firm welcomes the opportunity to discuss individual cases further.